Cite
HARVARD Citation
Flisiak, R. et al. (2016). Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Alimentary pharmacology & therapeutics. 44 (9), pp. 946-956. [Online].